News Merck puts a price on its SpringWorks takeover bid Merck KGaA has confirmed that talks to buy SpringWorks have advanced to the 'late-stage' and are revolving around an offer of around $47 per share.
News With Merck circling, SpringWorks gets new drug approval Merck KGaA is talking to SpringWorks about a takeover, and FDA approval for a neurofibromatosis drug could have sweetened any potential deal.
News Isomorphic adds MSD to partner roster, and other deals It's been a busy dealmaking week, with Isomorphic Labs, fresh from a $5 billion financing, adding MSD to its list of research alliances.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.